Phillip Md Et Al Frost Acquires 67,434 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock in a transaction on Friday, February 28th. The stock was bought at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the transaction, the chief executive officer now directly owns 213,301,448 shares in the company, valued at $364,745,476.08. This represents a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, January 28th, Phillip Md Et Al Frost bought 47,537 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.56 per share, for a total transaction of $780,000.00.

OPKO Health Trading Up 6.7 %

NASDAQ:OPK opened at $1.74 on Friday. The company has a market capitalization of $1.19 billion, a PE ratio of -9.16 and a beta of 1.63. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.84. The stock’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.55. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. On average, research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP boosted its stake in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares during the period. Millennium Management LLC raised its stake in OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after acquiring an additional 2,112,382 shares during the last quarter. Northern Trust Corp lifted its position in OPKO Health by 4.7% during the 4th quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock worth $5,436,000 after acquiring an additional 164,847 shares during the period. Lazard Asset Management LLC increased its holdings in shares of OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after purchasing an additional 1,502,342 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after purchasing an additional 949,671 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on OPK shares. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.